ECancer Interview: Prospective validation of single mouse testing by the paediatric preclinical testing consortium (Houghton)
Dr. Peter Houghton speaks to ecancer about the prospective validation of single mouse testing by the pediatric preclinical testing consortium; a study that was presented at ENA 2020 this year.
Dr. Houghton initially explains the rationale behind this study and talks about how it was tested that using a single mouse for studying drug efficacy in pediatric cancers can give the same results as using more mice.
He considers it to be a great scientific breakthrough that can change how pre-clinical testing is done currently. He then speaks of the key results obtained from this study and how they can impact the future.
Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.
Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.